Comparative Pharmacology
Head-to-head clinical analysis: CLOXAPEN versus STAPHCILLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOXAPEN versus STAPHCILLIN.
CLOXAPEN vs STAPHCILLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cloxapen inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBPs involved in the transpeptidation step of peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamases.
Semisynthetic penicillin; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
Oral: 250-500 mg every 6 hours. IV: 1-2 g every 4-6 hours.
1-2 g IV every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life 1.5-2 hours; prolonged to 2.5-4 hours in severe renal impairment; clinical context: requires frequent dosing in normal renal function
0.5-1 hour in adults with normal renal function; prolonged to 2-4 hours in renal impairment. Infants: 1-2 hours.
Renal 70-80% as unchanged drug and active metabolite; biliary 5-10%; fecal <5%
Primarily renal (70-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary excretion (<5%) and fecal elimination (<1%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic